- Home
- AVD vs STTK Comparison
AVD vs STTK Comparison
Compare AVD & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVD
- STTK
- Stock Information
- Founded
- AVD 1969
- STTK 2016
- Country
- AVD United States
- STTK United States
- Employees
- AVD N/A
- STTK N/A
- Industry
- AVD Agricultural Chemicals
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- AVD Industrials
- STTK Health Care
- Exchange
- AVD Nasdaq
- STTK Nasdaq
- Market Cap
- AVD 165.8M
- STTK 56.8M
- IPO Year
- AVD N/A
- STTK 2020
- Fundamental
- Price
- AVD $4.80
- STTK $1.12
- Analyst Decision
- AVD Strong Buy
- STTK Hold
- Analyst Count
- AVD 3
- STTK 3
- Target Price
- AVD $16.67
- STTK $2.00
- AVG Volume (30 Days)
- AVD 328.5K
- STTK 182.2K
- Earning Date
- AVD 11-11-2024
- STTK 02-27-2025
- Dividend Yield
- AVD 1.27%
- STTK N/A
- EPS Growth
- AVD N/A
- STTK N/A
- EPS
- AVD N/A
- STTK N/A
- Revenue
- AVD $553,839,000.00
- STTK $6,435,000.00
- Revenue This Year
- AVD N/A
- STTK $313.04
- Revenue Next Year
- AVD $5.31
- STTK N/A
- P/E Ratio
- AVD N/A
- STTK N/A
- Revenue Growth
- AVD N/A
- STTK 382.75
- 52 Week Low
- AVD $4.26
- STTK $0.94
- 52 Week High
- AVD $14.28
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- AVD 46.81
- STTK 43.75
- Support Level
- AVD $4.46
- STTK $1.13
- Resistance Level
- AVD $5.01
- STTK $1.39
- Average True Range (ATR)
- AVD 0.24
- STTK 0.11
- MACD
- AVD 0.06
- STTK 0.00
- Stochastic Oscillator
- AVD 72.00
- STTK 18.18
About AVD American Vanguard Corporation ($0.10 Par Value)
American Vanguard Corp is a United States-based diversified specialty and agricultural products company. It manufactures and formulates chemicals for crops, turf and ornamental plants, and human and animal health protection. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.